Safety of Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicle Injection for Lumbar Facet Joint Pain

Wilson, James E; Today, Bobbie A; Salazar, Maria; Kuo, Jonathann; Ransom, John T; Lightner, Amy L; Chen, Grace; Wong, Anita

doi:10.2217/rme-2023-0110

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phillips et al demonstrated that administration (epidural) of BM-MSC-Exo in lumbar and cervical radiculopathy patients is safe and resulted in decreased pain and improved function at 1-month follow-up compared to the baseline [26]. Wilson et al showed that administration (in the facet joint space) of BM-MSC-EV in lumbar facet joint patients is safe and led to significant improvements in pain and function at three months follow-up compared to the baseline [27]. The results from these studies are in accordance with the literature demonstrating the efficacy of MSCs in ameliorating low back pain [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

“…Wilson et al [27], in a single center, open-label, investigator-initiated, prospective, non-randomized study, evaluated the safety and efficacy of single injection in the facet joint space of human bone marrow mesenchymal stem cells-derived extracellular vesicles (BM-MSC-EV) (60-80 billion EVs/mL) in patients with lumbar facet joint pain. Twenty patients with lumbar facet joint pain (L4-L5 or L5-S1) confirmed via review of physical examination, medical history, and MRI imaging were included.…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Exosomes for the Management of Low Back Pain: A Review of Current Clinical Evidence

Gupta

2024

Cureus

View full text Add to dashboard Cite

Low back pain affects millions of people, creating an enormous financial burden on the global healthcare system. Traditional treatment modalities are short-lived and have shortcomings. Recently, orthobiologics, including extracellular vesicles or exosomes derived from mesenchymal stem cells, have markedly increased for managing musculoskeletal conditions. Here, the primary aim is to review the outcomes of clinical studies using extracellular vesicles or exosomes for treating low back pain. Numerous databases (Scopus, PubMed, Web of Science, Embase, and Google Scholar) were searched using terms for the intervention 'exosomes' and the treatment 'low back pain' for studies published in English to March 18, 2024. Articles utilizing exosomes for the management of low back pain were included. Articles not utilizing exosomes, not explicitly stating the presence of exosomes in their formulation, or not targeting low back pain were excluded. Two articles that met our pre-defined criteria were included in this review. The results showed that administering extracellular vesicles or exosomes is safe and potentially effective in patients suffering from low back pain. Yet, more sufficiently powered, multi-center, prospective, randomized, and nonrandomized trials with longer follow-up are essential to assess the long-term safety and efficacy of extracellular vesicles or exosomes derived from various sources and to support its routine clinical use for managing low back pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Clinical Studiesmentioning

confidence: 99%

Exosomes for the Management of Low Back Pain: A Review of Current Clinical Evidence

Gupta

2024

Cureus

View full text Add to dashboard Cite

show abstract

miRNA packaging into small extracellular vesicles and implications in pain

DaCunza,

Wickman,

Ajit

2024

PR9

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are a heterogenous group of lipid bilayer bound particles naturally released by cells. These vesicles are classified based on their biogenesis pathway and diameter. The overlap in size of exosomes generated from the exosomal pathway and macrovesicles that are pinched off from the surface of the plasma membrane makes it challenging to isolate pure populations. Hence, isolated vesicles that are less than 200 nm are called small extracellular vesicles (sEVs). Extracellular vesicles transport a variety of cargo molecules, and multiple mechanisms govern the packaging of cargo into sEVs. Here, we discuss the current understanding of how miRNAs are targeted into sEVs, including the role of RNA binding proteins and EXOmotif sequences present in miRNAs in sEV loading. Several studies in human pain disorders and rodent models of pain have reported alterations in sEV cargo, including miRNAs. The sorting mechanisms and target regulation of miR-939, a miRNA altered in individuals with complex regional pain syndrome, is discussed in the context of inflammation. We also provide a broad overview of the therapeutic strategies being pursued to utilize sEVs in the clinic and the work needed to further our understanding of EVs to successfully deploy sEVs as a pain therapeutic.

show abstract

Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group

D'Souza,

Her,

Hussain

et al. 2024

JPR

View full text Add to dashboard Cite

Safety of Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicle Injection for Lumbar Facet Joint Pain

Cited by 4 publications

References 26 publications

Exosomes for the Management of Low Back Pain: A Review of Current Clinical Evidence

Exosomes for the Management of Low Back Pain: A Review of Current Clinical Evidence

miRNA packaging into small extracellular vesicles and implications in pain

Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group

Contact Info

Product

Resources

About